how big is Gennex Lab.?

As of Jun 06, Gennex Laboratories Ltd has a market capitalization of 299.32 Cr, with recent net sales of 148.34 Cr and net profit of 16.99 Cr over the last four quarters. Shareholder's funds are 170.38 Cr, and total assets are 229.76 Cr as of Mar 2024.

Market Cap: As of Jun 06, Gennex Laboratories Ltd has a market capitalization of 299.32 Cr, classifying it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Gennex Laboratories Ltd reported a sum of Net Sales amounting to 148.34 Cr and a sum of Net Profit totaling 16.99 Cr. This data is on a Consolidated basis.<BR><BR>Balance Sheet Snapshot: The balance sheet data is also on a Consolidated basis for the latest annual period ending in Mar 2024. Shareholder's Funds are reported at 170.38 Cr, while Total Assets stand at 229.76 Cr.

Has Gennex Lab. declared dividend?

No Dividend History Available

What is the technical trend for Gennex Lab.?

As of May 12, 2025, Gennex Lab's trend is mildly bearish, with daily moving averages and Bollinger Bands indicating bearishness, while mixed signals from MACD and KST suggest caution in the near term.

As of 12 May 2025, the technical trend for Gennex Lab has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the daily moving averages indicating bearishness and the Bollinger Bands showing a bearish trend on both weekly and monthly time frames. While the weekly MACD and KST are mildly bullish, the overall monthly indicators, including MACD and KST, remain mildly bearish, suggesting a lack of strong upward momentum. The Dow Theory shows a mildly bullish signal on the weekly chart but no trend on the monthly, indicating mixed signals. Overall, the strength of the bearish trend is moderate, with key indicators pointing towards caution in the near term.

Who are the peers of the Gennex Lab.?

Gennex Lab.'s peers include Lyka Labs, SMS Lifesciences, Zenotech Lab., and others. Gennex Lab. shows below average management risk, good growth, and a 1-year return of -4.45%, while SMS Lifesciences leads with a 1-year return of 55.34%.

Peers: The peers of Gennex Lab. are Lyka Labs, SMS Lifesciences, Zenotech Lab., Medico Remedies, Kimia Bioscien., Everest Organics, Trident Lifeline, Ambalal Sarabhai, and Influx Health.<BR><BR>Quality Snapshot: Below Average management risk is observed at Gennex Lab., Kimia Bioscien., and Ambalal Sarabhai, while Average management risk is found at SMS Lifesciences, Zenotech Lab., Everest Organics, Trident Lifeline, and the rest. Good growth is noted at Gennex Lab. and Trident Lifeline, while Average growth is seen at Lyka Labs, Medico Remedies, and the rest. Excellent capital structure is present at Gennex Lab., while Good capital structure is found at Zenotech Lab., Medico Remedies, Trident Lifeline, and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is SMS Lifesciences at 55.34%, while the lowest is Ambalal Sarabhai at -49.34%. Gennex Lab.'s 1-year return is -4.45%, which is higher than Ambalal Sarabhai's but lower than SMS Lifesciences'. Additionally, peers such as Medico Remedies, Ambalal Sarabhai, and Gennex Lab. have negative six-month returns.

Who are in the management team of Gennex Lab.?

As of March 2022, the management team of Gennex Lab includes Chairman & Managing Director Arihant Baid, Whole-time Director T M GopalaKrishnan, and five independent directors: Y Ravinder Reddy, Sadhana Bhansali, A S Nageswar Rao, and A Ranga Rao Pantulu.

As of March 2022, the management team of Gennex Lab includes the following individuals:<BR><BR>1. Arihant Baid - Chairman & Managing Director<BR>2. T M GopalaKrishnan - Whole-time Director<BR>3. Y Ravinder Reddy - Independent Director<BR>4. Sadhana Bhansali - Independent Director<BR>5. A S Nageswar Rao - Independent Director<BR>6. A Ranga Rao Pantulu - Independent Director<BR><BR>Arihant Baid and T M GopalaKrishnan hold key executive positions, while the others serve as independent directors.

What does Gennex Lab. do?

Gennex Laboratories Ltd is a micro-cap manufacturer and exporter of active pharmaceutical ingredients and intermediates, incorporated in 1985 and publicly listed since 2007. As of March 2025, it reported net sales of 442 Cr and a net profit of 23 Cr.

Overview: <BR>Gennex Laboratories Ltd is a leading manufacturer and exporter of active pharmaceutical ingredients and intermediates in the Pharmaceuticals & Biotechnology industry, categorized as a Micro Cap company.<BR><BR>History: <BR>Gennex Laboratories Limited was incorporated on June 25, 1985, and was converted into a Public Limited Company in 2007, changing its name from Prudential Pharmaceuticals Limited. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 442 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 23 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: INR 323 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 18.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.16 <BR>Return on Equity: 9.39% <BR>Price to Book: 1.78 <BR><BR>Contact Details: <BR>Address: Survey No 133 Bollaram, Jinnaram Mandal Medak Telangana : 502325 <BR>Tel: 91-8458-279406/279516 <BR>Website: http://www.gennexlab.com

Who are the top shareholders of the Gennex Lab.?

The top shareholders of Gennex Lab are Premier Fiscal Services Private Limited with 16.5%, Jms Mines & Minerals Private Limited at 3.47%, and individual investors who collectively own 62.19%. There are no holdings from mutual funds or foreign institutional investors.

The top shareholders of Gennex Lab include Premier Fiscal Services Private Limited, which holds the highest stake among promoters at 16.5%. Additionally, Jms Mines & Minerals Private Limited is the highest public shareholder with a holding of 3.47%. Individual investors collectively own 62.19% of the company. It's also noteworthy that there are no holdings from mutual funds or foreign institutional investors.

Are Gennex Lab. latest results good or bad?

Gennex Laboratories' latest results show a 20.69% increase in net sales to Rs 34.18 crore, but a concerning 21.23% decline in Profit After Tax to Rs 7.03 crore, raising questions about profitability. The stock is rated as a 'Sell' by MarketsMOJO, indicating a cautious outlook on the company's financial health.

Gennex Laboratories' latest results present a mixed picture. On the positive side, the company reported net sales of Rs 34.18 crore, which reflects a year-on-year growth of 20.69%. This indicates that the company is generating more revenue compared to the previous year, which is a good sign for its sales performance.<BR><BR>However, there are notable concerns as well. The Profit After Tax (PAT) has declined by 21.23% year-on-year, standing at Rs 7.03 crore. This significant drop raises questions about the company's profitability. Additionally, a large portion of the Profit Before Tax (PBT)—38.84%—comes from non-operating income, which could indicate potential issues with the sustainability of its core business operations.<BR><BR>Overall, while the growth in net sales is encouraging, the decline in profitability and reliance on non-operating income suggest that Gennex Laboratories is facing challenges. The stock is currently rated as a 'Sell' by MarketsMOJO, reflecting a cautious outlook on the company's financial health.

When is the next results date for Gennex Lab.?

The next results date for Gennex Lab. is 14 November 2025.

The next results date for Gennex Lab. is scheduled for 14 November 2025.

Is Gennex Lab. overvalued or undervalued?

As of November 7, 2025, Gennex Lab's valuation is considered attractive with a PE ratio of 19.66, favorable compared to peers like Sun Pharma and Divi's Lab, and despite recent underperformance, it has shown strong long-term growth of 296.11% over five years.

As of 7 November 2025, Gennex Lab's valuation grade has moved from very attractive to attractive. The company appears to be fairly valued based on its current metrics. The PE ratio stands at 19.66, the EV to EBIT ratio is 15.54, and the EV to EBITDA ratio is 13.64. <BR><BR>In comparison to its peers, Gennex Lab's valuation is more favorable than Sun Pharma, which has a PE ratio of 35.17, and Divi's Lab, which is significantly more expensive at a PE of 71.11. Other peers like Cipla and Dr. Reddy's Labs have PE ratios of 22.33 and 17.43, respectively, indicating that Gennex Lab is positioned competitively within the industry. Despite recent underperformance relative to the Sensex, particularly over the past year, the long-term returns of 296.11% over five years suggest a strong growth trajectory, reinforcing its current valuation stance.

How has been the historical performance of Gennex Lab.?

Gennex Lab has demonstrated significant growth in net sales and profitability, with net sales increasing from 55.62 Cr in Mar'20 to 137.90 Cr in Mar'25, and profit after tax rising from 1.86 Cr to 18.12 Cr in the same period, despite rising raw material costs and negative cash flow in recent years. Total assets grew from 56.94 Cr to 255.86 Cr, indicating strong overall financial expansion.

Answer:<BR>The historical performance of Gennex Lab shows significant growth in net sales and profitability over the years.<BR><BR>Breakdown:<BR>Gennex Lab's net sales have increased from 55.62 Cr in Mar'20 to 137.90 Cr in Mar'25, demonstrating a consistent upward trend. Total operating income has mirrored this growth, rising from 55.62 Cr in Mar'20 to 137.90 Cr in Mar'25. However, the raw material costs have also escalated, reaching 100.59 Cr in Mar'25 from 34.19 Cr in Mar'21. Despite rising costs, the operating profit (PBDIT) has shown improvement, climbing to 27.14 Cr in Mar'25 from 4.20 Cr in Mar'20. Profit before tax has also increased significantly, reaching 21.40 Cr in Mar'25 compared to 2.55 Cr in Mar'20. The profit after tax has followed suit, growing from 1.86 Cr in Mar'20 to 18.12 Cr in Mar'25. The company's total assets have expanded from 56.94 Cr in Mar'20 to 255.86 Cr in Mar'25, while total liabilities have increased from 56.94 Cr to 10.22 Cr in the same period. Cash flow from operating activities has been negative in recent years, with a cash outflow of 10.00 Cr in Mar'25, contrasting with a positive cash flow of 23.00 Cr in Mar'23. Overall, Gennex Lab has shown robust growth in sales and profitability, despite challenges in managing costs and cash flow.

Should I buy, sell or hold Gennex Lab.?

Which are the latest news on Gennex Lab.?

Why is Gennex Lab. falling/rising?

As of 04-Dec, Gennex Laboratories Ltd's stock price is declining, currently at 13.49, reflecting a 3.85% decrease. The stock has underperformed significantly year-to-date and relative to its sector, despite a recent increase in investor participation.

As of 04-Dec, Gennex Laboratories Ltd's stock price is falling, currently at 13.49, which reflects a decrease of 0.54 or 3.85%. This decline is evident in the stock's performance over various periods, particularly in the last month where it has dropped by 10.72%, while the benchmark Sensex has increased by 2.16%. Year-to-date, the stock has also underperformed significantly, with a decline of 17.44% compared to the Sensex's gain of 9.12%. <BR><BR>Today's performance indicates that Gennex Laboratories has underperformed its sector by 4.14%. Although the stock is trading higher than its 100-day and 200-day moving averages, it is lower than its 5-day, 20-day, and 50-day moving averages, suggesting a short-term weakness. However, there has been a rise in investor participation, with a delivery volume increase of 41.61% compared to the 5-day average, which may indicate some interest despite the overall downward trend. <BR><BR>In summary, the combination of recent poor performance relative to both the market and its sector, along with the significant year-to-date decline, contributes to the current falling stock price of Gennex Laboratories Ltd.